Qwen

Designing Targeted Nebulized Antimicrobials: An Evidence-Based Guide to Formulating Sprays for Ear, Nose, Throat, and Lung Infections

Candidate Active Ingredients: A Comparative Efficacy and Safety Analysis

The primary challenge in designing an effective antimicrobial spray for the respiratory tract is navigating the inherent conflict between maximizing pathogen-killing potential and preserving the delicate integrity of mucosal surfaces [17]. The respiratory epithelium, from the nasal passages to the alveoli, relies on a complex system of cilia, mucus, and cellular defenses to protect the host [12]. Any therapeutic agent that disrupts this system can inadvertently worsen infection by impairing mucociliary clearance [12][21][23]. Therefore, the selection of an active ingredient must be guided by a rigorous evaluation of its mechanism of action, spectrum of activity, and, most critically, its cytotoxicity profile at concentrations relevant for nebulization. The analysis of available evidence reveals several classes of compounds that offer a favorable balance of broad-spectrum efficacy and mucosal tolerance, including electrochemically generated oxidizing agents, established topical antiseptics, and natural product extracts with multi-modal actions.

Among the most compelling candidates are hypochlorous acid (HOCl) and N-chlorotaurine (NCT), which are generated through electrochemical processes. HOCl is a potent biocide with proven virucidal, bactericidal, and fungicidal properties [1]. Its mechanism of action involves multiple oxidative pathways, such as the oxidation of sulfhydryl enzymes and amino acids, ring chlorination of aromatic amino acids, and damage to DNA and respiratory components, leading to microbial death [1]. This multi-target approach makes the development of resistance unlikely [1]. Notably, HOCl demonstrates remarkable efficacy against SARS-CoV-2, achieving a 4–5 log reduction in viral titer within 15–30 seconds in vitro [1]. Its safety profile is exceptionally broad. Inhalative toxicity studies show that aerosolized HOCl at concentrations below 0.21 ppm (equivalent to 0.5 mg/m^3) is harmless to humans and does not cause tissue irritation [1].

Furthermore, cultured human cells from the umbilical vein have shown tissue compatibility with HOCl up to 1,300 ppm [1]. For mucosal applications, conservative strategies suggest using concentrations up to 500 μM (~26 ppm) for mild effects, while solutions containing up to ~300 ppm at pH 6.5 have been found safe for respiratory tissue without affecting cellular viability or morphology [8]. Commercial products, such as mouthwashes containing 105 ppm and nasal sprays with 440 ppm, validate the practical application of these safe concentration ranges [8]. The stability of HOCl is highly dependent on pH; it predominates in acidic conditions (pH < 5), which aligns with the slightly acidic nature of some body surfaces and enhances its biocidal activity compared to its conjugate base, the hypochlorite anion (OCl^-), which is less effective but more cytotoxic [1][128].

N-chlorotaurine (NCT) is another endogenous halogenating agent with a similarly impressive safety record and broad-spectrum activity [10]. Like HOCl, it acts through oxidative mechanisms and has demonstrated efficacy against Gram-positive and Gram-negative bacteria, fungi, and viruses without inducing resistance [10][11]. A double-blind randomized Phase I clinical study involving healthy volunteers confirmed its excellent tolerability when inhaled as a 1% aqueous solution over five consecutive days [11]. The study reported no significant changes in objective lung function parameters, blood oxygenation, or systemic absorption, with pharmacokinetic analysis showing undetectable levels of NCT in the systemic circulation [11]. The primary subjective effect was a mild chlorine taste, which decreased with repeated use [11]. Histological investigations in a pig model after four hours of inhalation revealed no differences between NCT-treated groups and saline controls [10]. This confirms its role as a locally acting, topically administered agent with minimal systemic risk [10]. While NCT's own activity can be enhanced in inflammatory exudates by adding ammonium chloride to form monochloramine, one study noted that a combination of 1% NCT + 1% NH_4Cl caused a statistically significant decrease in blood oxygenation, highlighting the need for careful formulation even with well-tolerated agents [10].

Povidone-Iodine (PVP-I) represents a class of well-established topical antiseptics with extensive clinical data supporting its use on mucosal surfaces [8]. It is effective against a wide range of pathogens and international guidelines recommend its use in tolerable concentrations between 0.23% and 1.25% inside the nose and mouth for prophylaxis and early treatment of infections [8][9]. Clinical trials have investigated its ability to reduce nasopharyngeal viral load in patients with COVID-19, providing a strong evidence base for its application in the upper respiratory tract [9]. An in vitro study specifically demonstrated that a 0.5% PVP-I solution could be safely applied to cells of the nasal

epithelium [115]. However, it is important to note that not all iodine-based preparations are equal; Betadine, a brand name for PVP-I, has been reported to have a ciliotoxic effect on ciliated human respiratory cells, underscoring the critical importance of specific formulation rather than generic compound names [60]. Despite this caveat, PVP-I remains a viable candidate for nasal and oral sprays due to its proven efficacy and established safety margins when used appropriately.

Finally, natural product extracts, particularly Pelargonium sidoides (EPs® 7630), offer a unique, multi-modal approach to treating respiratory infections [7]. Unlike single-mechanism agents, EPs® 7630 combines direct antimicrobial effects with immunomodulatory and anti-adhesive properties. In vitro studies show its efficacy against a broad range of gram-positive and gram-negative bacteria, as well as fungi like *Aspergillus niger* [7]. It also exhibits antiviral activity against rhinovirus, influenza virus, and SARS-CoV-2, with an IC50 of around 14 µg/mL for the latter [7]. Critically, it prevents bacterial adhesion to human epithelial cells and potently modulates the immune response by enhancing phagocytosis and intracellular killing by phagocytes, as well as modulating cytokine expression [7]. This dual action of directly targeting pathogens while boosting the host's innate defense is a significant advantage. Its safety profile is robust, with in vitro cytotoxicity studies reporting a high CC50 (cytotoxic concentration) of 557 µg/ml and hemolysis tests confirming low toxicity to blood cells at concentrations up to 100 µg/ml [7]. Importantly, clinical studies comparing EPs® 7630 to amoxicillin for acute bacterial rhinosinusitis found the herbal extract to be superior in both clinical and antimicrobial efficacy, suggesting it could serve as a potent alternative to conventional antibiotics [7].

In contrast to these promising candidates, numerous other substances demonstrate significant ciliotoxicity, making them poor choices for direct nebulization. Benzalkonium chloride (BKC), a common preservative in nasal sprays, induces cell lysis and causes ciliostasis in vitro [13] [16]. Even though some in vivo data suggests its effects may be attenuated by dilution and proteins in nasal secretions, its inclusion warrants extreme caution [12]. Hydrogen peroxide (H_2O_2), despite its antimicrobial properties, significantly impairs ciliary motility and flow, with brief exposure causing cessation of ciliary beat frequency [12] [21] [23] [130]. Certain antibiotics and antifungals, including tobramycin, mupirocin, ofloxacin, amphotericin B, and clotrimazole, have also been reported to decrease or inhibit ciliary activity in human nasal epithelial cells [60]. Interestingly, one study found that commercially available intravenous tobramycin was ciliotoxic, whereas nebulized forms were not, reinforcing that safety is highly dependent on formulation, concentration, and vehicle, not just the active pharmaceutical ingredient itself [60]. These

examples illustrate that a substance's general reputation as an "antiseptic" is insufficient; its specific impact on mucociliary function must be evaluated.

Active Ingredient	Primary Mechanism of Action	Spectrum of Activity	Reported Ciliotoxicity / Mucosal Irritation	Key Safety Considerations
Hypochlorous Acid (HOCl)	Non-specific oxidation of proteins, lipids, DNA [1]	Broad-spectrum (Viruses, Bacteria, Fungi) [1]	Low at therapeutic concentrations; safe up to ~300 ppm [8]	Highly effective against SARS-CoV-2 (4-5 log reduction in seconds) [1]; stable at pH < 5 [128]
N-chlorotaurine (NCT)	Oxidative microbicidal activity [10]	Broad-spectrum (Viruses, Bacteria, Fungi, Protozoa) [10]	None reported at 1% concentration in clinical trials [11]	Excellent safety profile in human inhalation studies; rapidly inactivated locally in lungs [10] [11]
Povidone-Iodine (PVP-I)	Release of free iodine for oxidation [8]	Broad-spectrum (Viruses, Bacteria) [8]	Ciliotoxic effect reported for Betadine (PVP-I) [60]; safe at 0.5% in vitro [115]	Safe for nasal/oral use at 0.23-1.25%; clinical evidence for viral load reduction [8] [9]
Pelargonium sidoides (EPs® 7630)	Anti-adhesion, Immunomodulation, Direct antimicrobial [7]	Broad-spectrum (Viruses, Bacteria, Fungi) [7]	No significant ciliotoxicity reported; good tolerability [7]	Superior to amoxicillin in clinical trials for sinusitis [7]; high CC50 (557 µg/ml) [7]
Hydrogen Peroxide (H_2O_2)	Oxidation	Broad-spectrum (Bacteria, Fungi)	Significant impairment of ciliary motility and flow [122] [130]	Can cause cessation of ciliary beat frequency; not recommended for direct nebulization [123]
Benzalkonium Chloride (BKC)	Disruption of cell membrane	Broad-spectrum (Bacteria, Viruses)	Significant ciliotoxicity; causes ciliostasis and cell detachment [12] [13] [16]	Common preservative but carries a risk of mucosal damage; effects may be attenuated in vivo [12]

Ultimately, the principle of dose dependency is paramount. The safety of a substance is not an absolute property but is intrinsically linked to its concentration and the specific physiological environment of the target mucosa [17]. Formulations must be meticulously designed to operate within the established safe concentration windows for each anatomical site. The most viable candidates—HOCl, NCT, PVP-I, and EPs® 7630—each occupy distinct niches based on their unique profiles of efficacy, safety, and production feasibility, making them prime targets for developing specialized nebulizer formulations.

Formulation Principles for Safe and Effective Nebulization

The successful delivery of an antimicrobial agent via nebulization depends not only on the choice of the active ingredient but also on the precise control of the formulation's physicochemical properties. A poorly formulated solution, even with a potent active ingredient, can fail to reach its target site, cause local tissue damage, or trigger adverse systemic reactions. Key parameters that govern the safety and efficacy of nebulized therapies include osmolality, pH, viscosity, and the resulting aerosol particle characteristics. Adherence to established principles for these parameters is essential to ensure that the spray is both therapeutically effective and well-tolerated by the patient's sensitive mucosal surfaces [17] [58].

Isotonicity is a fundamental requirement for any solution intended for mucosal administration. The human body's fluids maintain a specific osmotic pressure, and delivering a solution that deviates significantly from this equilibrium can lead to cellular damage and irritation. For nebulized respiratory therapies, the target osmolality is approximately 300 mOsm/L, which corresponds to the tonicity of plasma and many bodily fluids [17]. Solutions that are hypertonic (higher solute concentration) or hypotonic (lower solute concentration) can cause pain, discomfort, and potentially impair mucociliary clearance [75]. Isotonicity is typically achieved by adjusting the concentration of salts, most commonly sodium chloride (NaCl), to create a 0.9% w/v solution, also known as normal saline [3] [101]. Dextrose is another excipient used for this purpose [3]. Saline solutions themselves have therapeutic value, as isotonic saline has been shown to increase mucociliary clearance and ciliary beat frequency, further supporting their use as a base for drug formulations [12] [75]. Conversely, hypertonic saline solutions (e.g., 3%) are used for different purposes, such as inducing sputum production or in the treatment of bronchiolitis, but they are generally less suitable as a base fluid for delivering drugs where minimizing irritation is a priority [109] [121].

The pH of a nebulized solution is equally critical, as it can profoundly affect both the stability and activity of the active ingredient as well as the health of the respiratory epithelium. The pH of the airway surface liquid (ASL) in the nasal passages is naturally slightly acidic, ranging from 5.5 to 6.5 [76]. To avoid irritation and preserve ciliary function, formulations intended for nasal delivery should be buffered to a pH within this range, ideally between 4.5 and 6.5 [76]. Deviating from this range can cause discomfort and may alter the function of the mucociliary escalator [58]. For instance, the efficacy of hypochlorous acid (HOCl) is highly pH-dependent; it is most effective and stable in acidic

conditions (pH < 5), where it exists predominantly as the uncharged molecule capable of penetrating bacterial cell walls [1] [8]. Therefore, a formulation containing HOCl would require careful buffering to maintain an optimal pH for its activity while remaining tolerable for the user. Phosphate Buffered Saline (PBS) is a commonly used buffer system to maintain a stable pH, often around 7.2-7.4, although this is slightly alkaline for nasal use [95]. For pulmonary delivery, especially in patients with asthma, it is crucial that the solution is both isotonic and has a neutral pH to prevent provocation of bronchoconstriction, a reaction that can be triggered by acidic or non-isotonic aerosols due to the lungs' limited buffering capacity [17].

Viscosity, or the thickness of the solution, influences how the liquid is atomized into an aerosol and how it behaves upon deposition on the mucosal surface. While higher viscosity can improve residence time and enhance the therapeutic effect of the drug at the site of action, it can also negatively impact nebulization performance [36]. For jet nebulizers, which rely on gas flow to generate droplets, increased viscosity can slow down the rate of aerosol output [17]. On the other hand, higher viscosity can sometimes lead to a decrease in the size of the generated particles [17]. The ideal viscosity is therefore a balance, allowing for efficient nebulization while providing sufficient contact time for the active ingredient to exert its effect. Excipients such as polymers or muco-penetrating agents like polyethylene glycol (PEG) can be used to modify viscosity and improve the dispersion of the drug [17]. Co-solvents like ethanol or propylene glycol may also be employed to aid in the dissolution of certain active ingredients, though their use requires careful consideration of mucosal tolerance [17] [59].

Perhaps the most critical aspect of formulation for pulmonary delivery is the generation of aerosol particles with the correct size distribution. The Mass Median Aerodynamic Diameter (MMAD) determines where the particles deposit in the respiratory tract. For effective delivery to the deep lung parenchyma, including the alveoli and terminal bronchioles, the MMAD must be in the optimal range of 1 to 5 μm [17] [30]. Particles larger than 5 μm tend to deposit in the upper airways (nasopharyngeal region) or the ventilation circuit of the nebulizer, failing to reach the target sites in the lungs [30]. Conversely, particles smaller than 0.5 μm are likely to be exhaled without depositing in the lung tissue, resulting in wasted medication and inefficient therapy [17]. The type of nebulizer used plays a significant role in determining the resulting particle size. Jet nebulizers, which use compressed gas, tend to produce larger droplets compared to vibrating mesh or ultrasonic nebulizers, which generate smaller, more uniform particles and are often preferred for deep lung delivery [30] [32]. For example, one study reported an MMAD of 1.74 μm for a jet nebulizer and 1.41 μm for a vibrating mesh device,

illustrating the difference in performance [32]. Solution properties such as surface tension and viscosity, along with nebulizer operational parameters like gas flow rate, all influence the final particle size [17] [31]. Higher gas pressures and flow rates generally result in smaller particle diameters [31].

A final, advanced consideration in formulation design is the interaction of the active ingredient with biological barriers, most notably the pulmonary surfactant layer in the alveoli. This layer, composed of lipids and proteins, is essential for reducing surface tension and preventing alveolar collapse. However, it can also act as a barrier to drug delivery. A study on antimicrobial photodynamic therapy demonstrated that hydrophobic photosensitizers became trapped within the surfactant layer, losing their efficacy, while a highly water-soluble agent, methylene blue, retained its full antimicrobial activity because it remained mobile within the aqueous phase [34]. This finding has profound implications for formulating drugs intended for deep lung delivery. It suggests that agents with high water solubility or those specifically engineered with muco-penetrating properties (e.g., via PEGylation to achieve a near-neutral surface charge) are more likely to be effective [17] [34]. This barrier highlights why simply nebulizing a drug is not always sufficient for successful pulmonary delivery; the drug's physicochemical properties must be compatible with the complex environment of the lung. By carefully controlling these formulation parameters—osmolality, pH, viscosity, and particle size—a developer can create a nebulized spray that maximizes therapeutic benefit while minimizing the risk of local and systemic adverse effects.

Site-Specific Formulations for Nasal Passages and Throat

The nasal passages and the throat (oropharynx) represent two interconnected yet physiologically distinct regions of the upper respiratory tract. While both are lined with ciliated pseudostratified epithelium and are exposed to similar airborne pathogens, their specific environments necessitate tailored formulation strategies to optimize safety and efficacy. The nasal cavity has a more sensitive mucosal lining with a naturally occurring pH of 5.5-6.5, making gentle formulations with a low risk of ciliotoxicity paramount [76]. In contrast, the oropharynx, while still sensitive, is somewhat more tolerant of agents with broader activity, providing greater flexibility in active ingredient selection. Nebulizer therapy is a well-established and safe topical treatment for inflammatory diseases of the

nose and sinuses, frequently used by otolaryngologists, which validates the chosen delivery method for these areas [19] [77].

For the nasal passages, the primary formulation goal is to deliver a therapeutic agent without disrupting the vital process of mucociliary clearance. This requires prioritizing agents with a high margin of safety. Based on the available evidence, several candidates are exceptionally well-suited for this application. Hypochlorous acid (HOCl) is a prime candidate due to its excellent safety profile at appropriate concentrations. Studies have shown that HOCl solutions up to approximately 300 ppm (5.72 mM) at a pH of 6.5 do not affect respiratory tissue, cellular viability, or morphology, indicating this range is safe for mucosal application [8]. Given the nasal mucus layer has a pH of 5.5-6.5, a buffered HOCl solution in this range would be ideal, combining efficacy with minimal irritation [76]. The ability of HOCl to stimulate neutrophil extracellular traps (NETs) and activate immune cells adds a beneficial immunomodulatory component to its direct antimicrobial action [8]. Similarly, Povidone-Iodine (PVP-I) is widely considered safe for topical application in the nose at concentrations between 0.23% and 1.25% [8]. An in vitro study specifically demonstrated that a 0.5% PVP-I solution could be safely applied to human nasal epithelial cells, making it a viable option for reducing viral load [115]. Pelargonium sidoides (EPs® 7630) also presents a strong case for nasal use, given its demonstrated good tolerability and its unique ability to inhibit bacterial adhesion to host cells, a key step in the initiation of many respiratory infections [7]. A formulation for the nose should be isotonic (around 0.9% NaCl) and buffered to a pH of 5.5-6.5 to match the natural environment and maximize patient comfort [3] [76]. The aerosol should be generated with an MMAD suitable for deposition in the nasal cavity and paranasal sinuses, which generally falls within the lower end of the 1-5 μm range for deep penetration [17].

The formulation for the throat (oropharynx) can be less restrictive regarding mucosal tolerance, allowing for the use of agents with higher antimicrobial potency. The oropharyngeal mucosa is less densely populated with ciliated cells than the nasal cavity, making it more resilient to potential ciliotoxic effects. Consequently, all the top-tier candidates identified for the nasal passages—HOCl, NCT, PVP-I, and EPs® 7630—are also suitable for throat sprays. However, the concentration of the active ingredient can be optimized for maximum efficacy. For instance, a mouthwash containing HOCl at concentrations of 0.01–0.02% (100–200 ppm) has been shown to be effective, and commercial mouthwashes containing CHX, PVP-I, and HP all had significant positive effects on reducing salivary SARS-CoV-2 viral load [1] [28]. This provides a precedent for using moderately concentrated antiseptic solutions in the oral cavity and oropharynx. Chlorhexidine digluconate, another potent antiseptic, is widely used in preprocedural mouth rinses to effectively reduce bacterial contamination in aerosols generated during

dental treatments [29] [43]. While its long-term use can stain teeth, short-term application for treating infection is well-established. Similarly, povidone-iodine-based mouthrinses have been identified as an excellent option for reducing SARS-CoV-2 viral load in the oral cavity [66]. For a throat spray, a formulation based on HOCl at the higher end of the safe mucosal concentration range (approaching 300 ppm) or a PVP-I solution could provide powerful, broad-spectrum protection against both bacteria and viruses. The addition of Pelargonium sidoides offers the added benefit of preventing bacterial adhesion and boosting local immunity, which could be particularly useful in treating conditions like strep throat or viral pharyngitis [7]. As with nasal formulations, the throat spray should be isotonic and buffered to a neutral pH (around 7.0) to ensure comfort and prevent tissue irritation [58] [110].

Excipients play a crucial role in stabilizing these formulations. Buffers such as phosphate buffers are essential for maintaining the desired pH, which is critical for both the stability of the active ingredient (like HOCl) and the comfort of the user [95]. Isotonicity is maintained by dissolving sodium chloride or dextrose in the formulation [3]. For both nasal and throat applications, the nebulized particles should have a Mass Median Aerodynamic Diameter (MMAD) that ensures deposition in the target area. For the nasopharynx, this includes both the nasal vestibule and the posterior part of the throat, requiring an MMAD that allows for effective impaction and sedimentation in these regions, typically favoring smaller particles in the 1-3 μm range [17]. The choice of nebulizer will influence the final particle size, with vibrating mesh nebulizers being capable of producing very small droplets suitable for deep deposition if needed [30]. Ultimately, the decision between a nasal-only or a combined nasal/oropharyngeal formulation depends on the specific clinical goal. If the primary target is the sinuses, a nasal-focused formulation is required. If the concern is a widespread sore throat, a formulation targeting the oropharynx may be more appropriate. However, given the proximity of these structures, a versatile spray that is gentle enough for nasal use but potent enough for the throat could be a practical compromise, leveraging the safety profile of agents like HOCl or PVP-I.

Parameter	Nasal Passage Formulation	Throat (Oropharyngeal) Formulation
Target pH	5.5 - 6.5 (matches natural mucus) [76]	6.5 - 7.5 (neutral for comfort) [58]
Ideal Concentration Range	Low to moderate (e.g., HOCl ⩽ 300 ppm, PVP-I ⩽ 0.5%) [8] [115]	Moderate to high (e.g., HOCl up to 300 ppm, PVP-I up to 1.0%) [1] [66]
Preferred Active Ingredients	HOCl, PVP-I, EPs® 7630 [7] [8] [115]	HOCl, PVP-I, Chlorhexidine, EPs® 7630 [1] [7] [43] [66]
Key Considerations	High mucosal tolerance, low ciliotoxicity, preservation of MCC [12] [76]	Broader spectrum efficacy, prevention of bacterial adhesion [7]
Optimal MMAD	1 - 5 μm for deposition in nasal cavity and sinuses [17]	1 - 5 μm for deposition in oropharynx [17]

Advanced Formulations for Deep Lung Delivery

The delivery of therapeutics to the lower respiratory tract—the tracheobronchial tree and the delicate alveolar sacs—presents the most significant challenges in terms of both efficacy and safety. The deep lung environment is characterized by a highly sensitive epithelium, the presence of a pulmonary surfactant layer, and a risk of triggering adverse reactions like bronchoconstriction [17]. Therefore, formulations intended for deep lung deposition must be meticulously designed to ensure that aerosol particles reach their target and that the active ingredient is both safe and effective upon arrival. The Mass Median Aerodynamic Diameter (MMAD) is the single most critical parameter for successful pulmonary delivery, with an optimal range of 1 to 3 μm being necessary for particles to penetrate past the upper airways and deposit in the alveoli and terminal bronchioles [17] [30]. Larger particles (>5 μm) will impact in the oropharynx and trachea, while smaller particles (<0.5 μm) are largely exhaled, rendering them ineffective for local therapy [17]. The choice of nebulizer is also crucial; vibrating mesh and ultrasonic nebulizers are generally preferred over traditional jet nebulizers as they produce smaller, more uniform droplets that are better suited for deep lung penetration [30] [48].

Given the extreme sensitivity of the alveolar environment, the safety profile of the active ingredient becomes the paramount consideration. Among the candidates analyzed, N-chlorotaurine (NCT) emerges as a standout option for deep lung delivery. Its exceptional safety has been clinically validated in a Phase I trial where a 1% aqueous solution was well-tolerated by healthy volunteers over five days of inhalation [11]. The study found no significant changes in lung function, airway resistance, or blood oxygenation, and pharmacokinetic analysis confirmed that systemic absorption was undetectable,

indicating the agent acts locally and is rapidly inactivated [11]. This makes NCT an ideal candidate for a nebulized spray intended for the lungs. Its broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, coupled with its inability to induce resistance, provides a robust therapeutic profile [10] [11]. Another strong contender is hypochlorous acid (HOCl), provided it is used at sufficiently low concentrations. While highly effective, its potential for irritation increases with concentration. A conservative strategy would involve using HOCl at concentrations up to 500 μM (~26 ppm) as a base fluid, aiming for mild antimicrobial effects without causing classical log reduction through membrane disruption, thereby minimizing the risk of epithelial damage [8]. The WHO lists HOCl as a coronavirus-effective biocide, and the EPA includes it in its 'List N' of disinfectants for use against SARS-CoV-2, supporting its use as a potent agent [1].

The presence of pulmonary surfactant in the alveoli introduces a significant barrier to drug delivery. This lipid-protein film can trap hydrophobic molecules, preventing them from reaching their target [34]. One study demonstrated this phenomenon clearly, showing that most tested photosensitizers were rendered ineffective by becoming immobilized within the surfactant layer, while a highly water-soluble agent, methylene blue, retained its full efficacy [34]. This implies that for any formulation intended for the alveoli, the active ingredient must either be highly water-soluble or be formulated with carriers or modifiers that can help it penetrate the surfactant. Advanced formulation strategies could involve co-nebulizing the active ingredient with agents that modify surfactant properties or encapsulating the drug in carriers like liposomes. For example, Ambroxol, a mucolytic agent, has been shown to stimulate the production of pulmonary surfactant and can be delivered via nebulization [35]. A formulation co-aerosolizing Ambroxol with dipalmitoylphosphatidylcholine (DPPC), a major surfactant component, could potentially create a synergistic effect, improving both surfactant function and drug delivery [35]. Standard nebulized antibiotics like colistin, tobramycin, and vancomycin are used clinically for severe lower respiratory infections, confirming the viability of the route for delivering potent agents, though these are prescription-only and their home production is not advised [2] [30].

Formulation excipients must be chosen with extreme care for pulmonary applications. Many excipients considered safe for systemic administration, such as benzyl alcohol, ethanol, and propylene glycol, are not suitable for neonatal use and carry risks for adult populations, especially with chronic exposure [17] [59]. Preservatives like benzalkonium chloride (BKC) are known to be ciliotoxic and should be avoided in formulations destined for the lungs [12] [13]. Instead, sterile filtration is the preferred method for sterilizing solutions rather than heat-based methods like autoclaving, which could degrade sensitive active ingredients [10][21][19]. The solvent base is typically sterile water for injection, often

supplemented with electrolytes to adjust conductivity and improve nebulization efficiency [17]. Buffering is essential to maintain a neutral pH (around 7.0-7.4) to prevent irritation and bronchoconstriction [17]. For example, isotonic phosphate buffered saline (PBS) at pH 7.0–7.4 is a common base for antibiotic admixtures [110]. The overall formulation must be designed to be non-irritating, isotonic, and to produce an aerosol with an MMAD of 1-3 μm for optimal lung deposition [30]. The following table summarizes the key considerations for a deep lung formulation.

Parameter	Description & Importance	Recommended Approach / Values
Mass Median Aerodynamic Diameter (MMAD)	Determines deposition site. Must be 1-3 μm for deep lung (alveolar) delivery [17] [30].	Use vibrating mesh or ultrasonic nebulizer. Target MMAD of 1-3 μm [30].
Osmolality	Must be close to physiological levels (~300 mOsm/L) to prevent cellular damage and irritation [17].	Adjust with sodium chloride (0.9%) or dextrose [3].
pH	Must be neutral (pH 7.0-7.4) to prevent irritation and bronchoconstriction [17].	Use phosphate-buffered saline (PBS) or other suitable buffers [95] [110].
Active Ingredient Safety	Paramount due to extreme sensitivity of alveolar epithelium. Must be non-ciliotoxic and non-irritating [17].	Prioritize NCT (clinically proven safety) or very dilute HOCl [8] [11].
Excipients	Must be carefully selected for pulmonary safety. Avoid irritants like BKC, ethanol, and propylene glycol [59].	Use sterile-filtered water or saline. Avoid unnecessary additives [17] [102].
Surfactant Interaction	Pulmonary surfactant can trap hydrophobic drugs, reducing efficacy [34].	Prefer highly water-soluble agents (e.g., methylene blue) or use carriers [34].

In summary, developing a spray for deep lung delivery is a highly specialized task that requires prioritizing safety above all else. N-chlorotaurine stands out as the most promising active ingredient due to its proven safety and broad-spectrum activity in human trials. Hypochlorous acid is a strong secondary option if formulated at very low, conservative concentrations. The entire formulation, from the choice of active ingredient to the final sterile saline solution, must be optimized to ensure it is isotonic, neutral in pH, and generates an aerosol of the correct size for targeted alveolar deposition, all while avoiding any components known to be toxic or irritating to the lung tissue.

Topical Formulations for Otitis Externa

The external auditory canal, or ear, presents a unique anatomical and physiological environment that necessitates a distinct formulation strategy compared to the nasal passages, throat, or lungs. The ear canal is an approximately 1¼-inch-long, "S"-shaped tube that terminates at the tympanic membrane [74] [98]. Its primary defense against

infection is the protective cerumen (earwax) layer, which has demonstrated intrinsic antimicrobial properties against pathogens like *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Candida albicans* [44] [88]. Otitis externa, or swimmer's ear, is diffuse inflammation of this canal, often precipitated by moisture exposure and trauma, such as from cotton-tip applicators, which can damage the delicate skin and displace cerumen [71] [74]. Treatment focuses on eliminating infection and reducing inflammation, typically through the instillation of topical antimicrobial drops [70] [72]. Due to the confined space and the need for direct contact with the infected skin, a nebulized spray for the ear would function more like a fine misting of a topical solution rather than a deep lung inhalation.

Given the direct application to a localized site of infection, the formulation for otitis externa can prioritize potent antimicrobial activity over the stringent mucosal gentleness required for the nose or lungs. The primary goals are to deliver a broad-spectrum agent that can penetrate biofilms, which are common in persistent ear infections, and to provide a soothing effect [70]. Current standard-of-care treatments for otitis externa often involve combination ear drops containing a corticosteroid to reduce swelling and erythema alongside a topical antibiotic [53] [72]. Commonly prescribed antibiotics include fluoroquinolones like ofloxacin and ciprofloxacin, and combinations of neomycin and polymyxin B [52] [54] [55]. While these are prescription medications, they inform the type of activity required. An effective homemade or simple lab-produced spray should aim to replicate this broad-spectrum coverage.

One of the most promising candidates for a topical ear spray is silver nitrate. Topical application of 50% silver nitrate has been used safely and successfully in clinical settings for procedures like myringoplasty (healing of tympanic membrane perforations) and is considered safe with no reported complications [124][127]. Silver has long been recognized for its potent antimicrobial properties, and its use in wound care is well-established. A simple lab could prepare a dilute solution of silver nitrate in sterile saline for topical application to the ear canal, following strict aseptic technique. The concentration would need to be carefully controlled to be effective without causing chemical burns or excessive irritation to the sensitive skin of the ear canal.

Hypochlorous acid (HOCl) is another excellent candidate for an ear spray. Its proven broad-spectrum efficacy against bacteria, viruses, and fungi, combined with its relatively low toxicity at appropriate concentrations, makes it a versatile choice [1]. While specific studies on HOCl for otitis externa are not detailed in the provided sources, its success in other topical applications, such as wound cleansing approved by the FDA, supports its potential [1]. A formulation with a concentration of 100-300 ppm HOCl in sterile saline would be both effective and likely well-tolerated by the ear canal. The slightly acidic

nature of HOCl solutions can also help restore the natural acidic pH of the ear canal, which is a factor in preventing bacterial growth [74].

N-chlorotaurine (NCT) has also been tested in a relevant animal model. An inhaled solution of 1% NCT was well-tolerated in a pig model over four hours, with no significant adverse effects observed [10]. While this was an inhalation study, the excellent safety profile of NCT on respiratory tissue suggests it would be very well-tolerated when applied topically to the ear canal. Its broad-spectrum activity against bacteria and viruses would make it a valuable tool for treating otitis externa, which can be caused by either pathogen type [10]. A simple lab could reconstitute the lyophilized sodium salt of NCT in sterile, pyrogen-free distilled water to create a ready-to-use solution [10].

The formulation for an ear spray should be isotonic to minimize discomfort. Sodium chloride (0.9%) is the standard excipient for this purpose [101]. The pH should be adjusted to a level comfortable for the ear, likely in the neutral to slightly acidic range. Since the goal is direct topical contact rather than deep penetration, the particle size of the nebulized spray is less critical than in pulmonary delivery, though a fine mist is desirable for even distribution. The main challenge is ensuring that the formulation is both potent enough to kill pathogens and gentle enough to not cause further irritation to inflamed or damaged skin. The following table outlines the formulation priorities for an otitis externa spray.

Parameter	Description & Importance	Recommended Approach / Values
Primary Goal	Potent, broad-spectrum antimicrobial activity to treat localized infection.	Use agents with proven efficacy against bacteria (e.g., *P. aeruginosa*) and fungi [54] [73].
Active Ingredient Candidates	Silver Nitrate (topical), Hypochlorous Acid (HOCl), N-chlorotaurine (NCT).	Silver nitrate at a diluted concentration; HOCl at 100-300 ppm; NCT at a clinically tested concentration [1] [10] [124].
Adjunctive Therapy	Corticosteroids to reduce inflammation, swelling, and pain.	Not feasible for simple lab production; focus on antimicrobial action.
Base Solution	Sterile, isotonic saline to ensure comfort and prevent irritation.	0.9% w/v Sodium Chloride (NaCl) solution, sterilized by filtration [101] [102].
pH	Neutral to slightly acidic to match the ear's natural environment and minimize irritation.	Target pH of 5.5-7.0.
Delivery Method	Nebulizer spray for even distribution of the topical solution within the ear canal.	Fine mist application, similar to a nasal spray but designed for vertical insertion.

In conclusion, a topical spray for otitis externa should be formulated as a potent, broad-spectrum antiseptic solution designed for direct application. Silver nitrate, HOCl, and NCT are all highly suitable candidates. The formulation should be simple, consisting of the active ingredient dissolved in sterile, isotonic saline at a comfortable pH. This

approach leverages the strengths of modern antiseptic chemistry to create a therapeutic spray that addresses the specific needs of treating infection in the external ear canal.

Feasibility of Home and Simple Lab Production

The requirement for formulations to be producible in a home or simple laboratory setting imposes a significant constraint on the selection of active ingredients and the complexity of the manufacturing process. This criterion necessitates a clear distinction between synthesizing a precursor chemical from raw materials, which is often complex and hazardous, and performing a final preparation step, which is more accessible. The most feasible approach involves sourcing commercially available precursor chemicals or standardized extracts and performing a straightforward synthesis or reconstitution step under controlled conditions.

Among the most feasible options is the on-site generation of hypochlorous acid (HOCl). This process involves the electrolysis of a dilute saltwater solution, a procedure that can be accomplished in a basic laboratory setting with an electrochemical cell, power supply, and appropriate electrodes [1]. The reaction requires only three components: water, sodium chloride (table salt), and an electrical current. The chemical transformation is $2NaCl + 2H_2O \rightarrow 2NaOH + H_2 + Cl_2$, followed by the dissolution of chlorine gas in water to form hypochlorous acid ($Cl_2 + H_2O \leftrightarrow HCl + HOCl$). This method directly addresses the "home production" requirement, as the necessary equipment is not prohibitively expensive and the starting materials are common household items. The primary challenges lie in controlling the pH and concentration to produce a stable, safe, and effective solution, which would require simple laboratory glassware and test strips or a pH meter. This makes HOCl the most practical choice for a truly accessible, decentralized production model.

Another highly feasible option is the preparation of a stock solution from commercially available povidone-iodine (PVP-I). PVP-I is sold as a powder or in concentrated solutions for various medical uses [8]. A simple lab or even a well-equipped home kitchen could accurately weigh the PVP-I powder and dissolve it in a measured volume of sterile saline to create a concentrated stock solution. From this stock, final dilutions could be made to achieve the desired therapeutic concentration (e.g., 0.5%). This process requires only basic weighing equipment, volumetric flasks, and a source of sterile water or saline, all of which are achievable in a simple lab environment. The production of a Pelargonium sidoides (EPs® 7630) spray follows a similar pathway; the standardized plant extract is

typically supplied as a lyophilized (freeze-dried) powder that can be readily reconstituted in a suitable solvent, such as a buffered saline solution, according to the manufacturer's instructions [7]. This reconstitution process is straightforward and poses minimal technical difficulty, making it an excellent candidate for simple preparation.

In contrast, the production of N-chlorotaurine (NCT) is more complex and falls into the "simple lab" category but is beyond typical home production capabilities. NCT is synthesized chemically from the amino acid taurine [38]. While the provided context mentions the practical synthesis of long linear polyamines, which shares conceptual similarities, it does not detail the exact multi-step organic synthesis required to produce NCT from taurine and a chlorinating agent like sodium hypochlorite [38]. Such a process would require standard laboratory glassware, fume hoods for handling chemicals, precise temperature control, and purification techniques like recrystallization. While not impossible in a university or research lab, it is far more involved than generating HOCl or reconstituting a powder. Therefore, sourcing commercial-grade NCT powder would be the most pragmatic approach for a simple lab setting.

The production of nebulized antibiotics like colistin, tobramycin, or vancomycin, while technically possible in a sterile compounding pharmacy, is outside the scope of a simple lab or home production [2] [30]. These are complex peptide and glycoside molecules with specific stability requirements, and their preparation demands a high degree of aseptic technique, specialized equipment, and quality control testing to ensure sterility and potency. Attempting to produce such agents without proper training and facilities would pose a significant risk of contamination and therapeutic failure.

Beyond the synthesis of the active ingredient, the final formulation and sterilization steps are critical for safety. The preparation of any injectable or nebulized solution, even at home, must adhere to principles of asepsis to prevent microbial contamination. The most reliable method for sterilizing the final aqueous solution is membrane filtration using a filter with a pore size of 0.22 microns [102][119]. This physically removes bacteria and other contaminants. Heat sterilization methods like autoclaving are generally unsuitable for solutions containing heat-labile active ingredients like many of the candidates discussed (e.g., HOCl decomposes, proteins denature) [59] [102]. Therefore, a simple lab or home setup would need access to a filtration apparatus. The preparation environment itself should be as clean as possible, and all glassware and equipment must be properly cleaned and sterilized before use. Autoclaving glassware and solutions without pH control is a basic choice for routine sterilization [112][119]. The following table compares the production feasibility of the top candidate agents.

Active Ingredient	Production Complexity	Required Precursors/ Sources	Final Preparation Steps	Feasibility (Home/Basic Lab)
Hypochlorous Acid (HOCl)	Low	Table Salt (NaCl), Water, Electricity	Electrolysis of saltwater solution, pH adjustment, mixing.	**High.** Can be performed with simple electrochemical setup.
Povidone-Iodine (PVP-I)	Very Low	Commercial PVP-I powder or concentrate.	Weighing, dissolution in sterile saline, dilution.	**Very High.** Requires only basic weighing and mixing equipment.
Pelargonium sidoides (EPs® 7630)	Very Low	Commercial lyophilized extract powder.	Reconstitution of powder in sterile, buffered saline.	**Very High.** Extremely simple reconstitution process.
N-chlorotaurine (NCT)	High	Commercial taurine, sodium hypochlorite, other organic precursors.	Multi-step organic synthesis, purification (recrystallization).	**Low.** Suitable for a simple lab with organic chemistry expertise.
Silver Nitrate	Low	Commercial silver nitrate powder.	Weighing, dissolution in sterile saline, dilution.	**High.** Straightforward dissolution and dilution.

In summary, the feasibility of production strongly favors candidates that can be generated from simple electrochemical processes (HOCl) or prepared by dissolving/ reconstituting commercially available powders (PVP-I, EPs® 7630). These options align well with the goal of creating accessible, decentralized therapies. The production of more complex molecules like NCT, while possible in a formal laboratory, is less practical for the specified setting. Regardless of the chosen agent, adherence to sterile technique, particularly the use of sterile filtration for the final solution, is non-negotiable for ensuring patient safety.

Reference

1. Antimicrobial efficacy, mode of action and in vivo use ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10073986/
2. (PDF) Mixing and compatibility guide for commonly used ... https://www.researchgate.net/publication/41139379_Mixing_and_compatibility_guide_for_commonly_used_aerosolized_medications
3. Formulation and Product Development of Nebuliser Inhaler https://www.scribd.com/document/398740154/0e1150b37251922ab6194a05ad12efdb5a21

4. Aewcqrca 32 | PDF | Pharmacy | Medical Prescription https://www.scribd.com/document/394191426/aewcqrca32
5. Current antiviral therapies and promising drug candidates ... https://www.sciencedirect.com/science/article/pii/S1995820X25000033
6. A Phase 2a, Randomized, Placebo-Controlled Human ... https://link.springer.com/article/10.1007/s41030-025-00289-z
7. Unlocking the therapeutic potential of Pelargonium ... https://www.cell.com/heliyon/fulltext/S2405-8440(24)16585-1
8. Hypochlorous Acid (HOCl) as a Promising Respiratory ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12474219/
9. (PDF) Inhalation Formulation & Dosage of PVP Iodine for ... https://www.researchgate.net/publication/351970631_Inhalation_Formulation_Dosage_of_PVP_Iodine_for_Respiratory_Infections_Early-Stage_Treatment
10. Tolerability of inhaled N-chlorotaurine in the pig model - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC2722574/
11. Tolerability of inhaled N-chlorotaurine in humans https://journals.sagepub.com/doi/10.1177/1753466618778955
12. In Vitro Ciliotoxicity and Cytotoxicity Testing of Repeated ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8618987/
13. Developmental exposure to benzalkonium chloride ... https://www.sciencedirect.com/science/article/pii/S0147651325018913
14. Pharmacological characterization of the 3D MucilAir ... https://www.researchgate.net/publication/332176319_Pharmacological_characterization_of_the_3D_MucilAir_nasal_model
15. Opinion on Polyaminopropyl Biguanide (PHMB) - Submission III https://health.ec.europa.eu/system/files/2018-03/sccs_o_204_0.pdf
16. Nasal Toxicity of Benzalkonium Chloride | Request PDF https://www.researchgate.net/publication/8140823_Nasal_Toxicity_of_Benzalkonium_Chloride
17. Nebulised antibiotherapy - PubMed Central - NIH https://pmc.ncbi.nlm.nih.gov/articles/PMC5721216/
18. Use of nebulized antibiotics for acute infections in chronic ... https://www.sciencedirect.com/science/article/abs/pii/S0194599802002589
19. Survey of nebulizer therapy for nasal inflammatory diseases in ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8606268/

20. Use of Nebulized Antibiotics for Acute Infections in Chronic ... https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1067/mhn.2002.129738
21. Nebulization of antibiotics in management of sinusitis https://link.springer.com/article/10.1007/s11908-004-0007-4
22. Nebulized Antibiotics for the Treatment of Acute ... https://journals.sagepub.com/doi/10.1177/01455613020810091 3?icid=int.sj-abstract.citing-articles.78
23. Use of Nebulized Antibiotics for Acute Infections in Chronic ... https://www.researchgate.net/publication/10974552_Use_of_Nebulized_Antibiotics_for_Acute_Infections_in_Chronic_Sinusitis
24. Antiseptics: An expeditious third force in the prevention and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11532748/
25. N-acyl homoserine lactone signaling modulates bacterial ... https://www.nature.com/articles/s41522-025-00846-z
26. Oral Antiseptics against SARS-CoV-2: A Literature Review https://www.mdpi.com/1660-4601/19/14/8768
27. Antiviral effect of oral antiseptic solutions commonly used ... https://www.sciencedirect.com/science/article/pii/S2772559623000020
28. Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral ... https://link.springer.com/article/10.1186/s12879-023-08669-z
29. Melaleucae alternifoliae aetheroleum - AR - EMA https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf
30. How to Use Nebulized Antibiotics in Severe Respiratory ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9952454/
31. Nebulized inhalation drug delivery: clinical applications and ... https://pubs.rsc.org/en/content/articlehtml/2025/tb/d4tb01938e
32. Development of a Novel Bronchodilator Vaping Drug ... https://www.mdpi.com/1424-8247/16/12/1730
33. Inhalable point-of-care urinary diagnostic platform https://www.science.org/doi/10.1126/sciadv.adj9591
34. Lung surfactant negatively affects the photodynamic ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9231493/
35. Co-aerosolized Pulmonary Surfactant and Ambroxol for ... https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.577172/full

36. Formulation of a Composite Nasal Spray Enabling Enhanced ... https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202008304
37. Unmasking hazardous compounds in cannabidiol ... https://www.sciencedirect.com/science/article/abs/pii/S0039914025017643
38. Practical Synthesis of Antimicrobial Long Linear Polyamine ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10125363/
39. Preparation and Application of Biomass-based Sprayable ... https://www.sciopen.com/local/article_pdf/10.26599/PBM.2023.9260006.pdf
40. Lysozyme-Responsive Spray-Dried Chitosan Particles for ... https://pubs.acs.org/doi/10.1021/acsabm.9b00023
41. Core-Shell Micro/Nanocapsules: From Encapsulation to ... https://hal.science/hal-03978204v1/document
42. Laboratory Exercises in Microbiology https://www.researchgate.net/profile/Alaa-Niamah/post/Hi-everyone-does-anyone-have-protocols-for-the-following-tests/attachment/59d61d9779197b80779782f7/AS%3A271748644179985%401441801334827/download/Laboratory+Exercises+in+Microbiology+5thEd.pdf
43. Efficacy of preprocedural mouth rinses (Chlorhexidine ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12220137/
44. Antibacterial and antifungal properties of human cerumen https://www.researchgate.net/publication/23163187_Antibacterial_and_antifungal_properties_of_human_cerumen
45. Hydrogen Peroxide, Povidone-Iodine and Chlorhexidine ... https://www.mdpi.com/2075-1729/13/6/1230
46. Comparison of Chlorhexidine and Hydrogen Peroxide as ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9469440/
47. arikayce - accessdata.fda.gov https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207356s019lbl.pdf
48. Antibiotic loaded inhalable liposomal nanoparticles against ... https://www.sciencedirect.com/science/article/pii/S1773224724001850
49. Nasal sprays for treating COVID-19: a scientific note https://link.springer.com/article/10.1007/s43440-023-00463-7
50. Inhalable Nanotechnology-Based Drug Delivery Systems ... https://www.researchgate.net/publication/393620264_Inhalable_Nanotechnology-Based_Drug_Delivery_Systems_for_the_Treatment_of_Inflammatory_Lung_Diseases
51. Protein and peptide delivery through respiratory pathway https://doi.org/10.1016/B978-0-443-27416-9.00009-5

52. Identification and antimicrobial susceptibility of acute ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9442145/
53. Otitis Externa: Investigation and Evidence-Based Treatment https://www.researchgate.net/publication/332080670_Otitis_Externa_Investigation_and_Evidence-Based_Treatment
54. Biomedical application of materials for external auditory ... https://www.sciencedirect.com/science/article/pii/S2452199X24002019
55. Clinical practice guideline: Acute otitis externa https://journals.sagepub.com/doi/10.1016/j.otohns.2006.02.014
56. Current Perspective on Nasal Delivery Systems for Chronic ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7916625/
57. Inhalable Antimicrobials for Treatment of Bacterial Biofilm ... https://www.mdpi.com/1422-0067/17/10/1688
58. Administration of anti-infective agents through the inhaled ... https://www.researchgate.net/publication/6247597_Administration_of_anti-infective_agents_through_the_inhaled_route
59. Making Medicines Baby Size: The Challenges in Bridging ... https://www.mdpi.com/1422-0067/20/11/2688
60. Influence of Intranasal Drugs on Human Nasal Mucociliary ... https://pmc.ncbi.nlm.nih.gov/articles/PMC6439188/
61. Innovative approaches for beetroot (Beta Vulgaris L. ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12102054/
62. Immunomodulatory microneedle patch for periodontal ... https://www.sciencedirect.com/science/article/pii/S2590238521005798
63. Genomic characterization, in vitro, and preclinical evaluation ... https://link.springer.com/article/10.1186/s12941-024-00678-3
64. In vitro assessment of copper nanoparticles gel efficacy as ... https://www.tandfonline.com/doi/full/10.1080/16583655.2025.2549161
65. Biopolymeric Inhalable Dry Powders for Pulmonary Drug ... https://www.mdpi.com/1424-8247/17/12/1628
66. The effect of mouthrinses on severe acute respiratory ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8716175/
67. Efficacy of ListerineR Antiseptic in reducing viral ... https://www.researchgate.net/publication/7925458_Efficacy_of_ListerineR_Antiseptic_in_reducing_viral_contamination_of_saliva

68. Hydrogen Peroxide, Povidone-Iodine and Chlorhexidine Fail ... https://pubmed.ncbi.nlm.nih.gov/37374013/

69. (PDF) Antimicrobial Properties of Hive Products and Their ... https://www.researchgate.net/publication/388854240_Antimicrobial_Properties_of_Hive_Products_and_Their_Potential_Applications_in_Human_and_Veterinary_Medicine

70. Clinical Practice Guideline: Acute Otitis Externa https://www.researchgate.net/publication/260089863_Clinical_Practice_Guideline_Acute_Otitis_Externa

71. Review article: Topical antibiotic treatments for acute otitis ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9293151/

72. Otitis externa https://pch.health.wa.gov.au/For-health-professionals/Emergency-Department-Guidelines/Otitis-externa

73. Acute Otitis Externa: Efficacy and Tolerability of N- ... https://www.researchgate.net/publication/8578341_Acute_Otitis_Externa_Efficacy_and_Tolerability_of_N-Chlorotaurine_a_Novel_Endogenous_Antiseptic_Agent

74. Approach to otitis externa - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11477254/

75. Essentials in saline pharmacology for nasal or respiratory ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7998085/

76. Nasal Formulations for Drug Administration and ... https://www.researchgate.net/publication/339211433_Nasal_formulations_for_drug_administration_and_characterization_of_nasal_preparations_in_drug_delivery

77. Survey of nebulizer therapy for nasal inflammatory ... https://www.sciencedirect.com/science/article/abs/pii/S0385814621002698

78. From in vitro to in vivo Models of Bacterial Biofilm-Related ... https://pmc.ncbi.nlm.nih.gov/articles/PMC4235718/

79. Antimicrobial effect of Streptococcus salivarius outer ... https://www.sciencedirect.com/science/article/pii/S0264127523005920

80. Octenidine Lozenges Intended for Oral Administration ... https://www.mdpi.com/1422-0067/26/20/10045

81. Engineered probiotic overcomes pathogen defences using ... https://www.nature.com/articles/s41564-023-01583-9

82. Investigating the antimicrobial and anti-inflammatory effects ... https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1383959/full

83. Calcium − Powered Probiotics Reconfigure the Intestinal Niche ... https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202516911?af=R

84. Sprayable Hydrogel Sealant for Gastrointestinal Wound ... https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202311798
85. Animal Models for Candidiasis - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC4088949/
86. snail slime-based functional excipients for oral dosage forms https://www.sciencedirect.com/science/article/pii/S0378517325007513
87. Exploring the Influence of a Pomegranate Extract on ... https://www.mdpi.com/1420-3049/30/7/1634
88. Antibacterial and antifungal properties of human cerumen https://pubmed.ncbi.nlm.nih.gov/18694532/
89. Fabrication of Nanofibrous membrane using Stingless bee ... https://www.researchgate.net/publication/347695959_Fabrication_of_Nanofibrous_membrane_using_Stingless_bee_honey_and_Curcumin_for_wound_healing_applications
90. Chronic cough: A review and prospects https://journals.lww.com/md-journal/fulltext/2025/10100/chronic_cough__a_review_and_prospects.68.aspx
91. 33 Ophthalmic, Nasal, Inhalation, and Irrigation Solutions https://basicmedicalkey.com/33-ophthalmic-nasal-inhalation-and-irrigation-solutions/
92. Essentials in saline pharmacology for nasal or respiratory ... https://link.springer.com/article/10.1007/s00228-021-03102-3
93. (PDF) Concise Pocket Medical Dictionary https://www.academia.edu/11911834/Concise_Pocket_Medical_Dictionary
94. Standardized Pre-clinical Surgical Animal Model Protocol to ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10792889/
95. Influenza Virus - Springer Link https://link.springer.com/content/pdf/10.1007/978-1-61779-621-0.pdf
96. Ex vivo oral biofilm model for rapid screening of ... https://pubmed.ncbi.nlm.nih.gov/39971954/
97. (PDF) Ex vivo oral biofilm model for rapid screening of ... https://www.researchgate.net/publication/389137641_Ex_vivo_oral_biofilm_model_for_rapid_screening_of_antimicrobial_agents_including_natural_cranberry_polyphenols
98. dosage form final Flashcards https://quizlet.com/511750762/dosage-form-final-flash-cards/
99. Topical Drug Delivery for Chronic Rhinosinusitis - Springer Link https://link.springer.com/article/10.1007/s40136-012-0003-4

100. Treatment of Chronic Rhinosinusitis Refractory to Other ... https://www.researchgate.net/publication/11791518_Treatment_of_Chronic_Rhinosinusitis_Refractory_to_Other_Treatments_with_Topical_Antibiotic_Therapy_Delivered_by_Means_of_a_Large-Particle_Nebulizer_Results_of_a_Controlled_Trial
101. Environmental-Microbiology-Methods-and-Protocols. ... https://www.researchgate.net/profile/Rakesh-S-Pillai/publication/256842590_Environmental-Microbiology-Methods-and-Protocols/links/00b7d523edc4be687e000000/Environmental-Microbiology-Methods-and-Protocols.pdf
102. Analytical methods for paralytic shellfish poisons https://unesdoc.unesco.org/ark:/48223/pf0000136169
103. Multi Text8 E10 d300 Vs2e-4 Lr1e-5 Margin1.words | PDF https://www.scribd.com/document/480950803/multi-text8-e10-d300-vs2e-4-lr1e-5-margin1-words-txt
104. bing.txt ftp://ftp.cs.princeton.edu/pub/cs226/autocomplete/bing.txt
105. Manual of Infection Prevention and Control (PDFDrive) | PDF https://www.scribd.com/document/511128041/Manual-of-infection-prevention-and-control-PDFDrive
106. Medical interventions for chronic rhinosinusitis in cystic fibrosis https://pmc.ncbi.nlm.nih.gov/articles/PMC8989145/
107. Phytomedicine ELOM − 080 in Acute Viral Rhinosinusitis: A ... https://onlinelibrary.wiley.com/doi/full/10.1002/lary.30418
108. Efficacy and Safety of Long-Term Low-Dose Clarithromycin ... https://journals.sagepub.com/doi/10.1177/01455613211032020
109. Nebulised hypertonic saline solution for acute bronchiolitis ... https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006458.pub5/references
110. Bhutan-Pandemic-Preparedness-and-Response-Plan- ... https://documents1.worldbank.org/curated/en/202911611121891975/pdf/Bhutan-Pandemic-Preparedness-and-Response-Plan-BPPRP-and-Standard-Operating-Procedures.pdf
111. Health and Safety in the Science Classroom https://open.alberta.ca/dataset/2ade25c2-7dbb-4a1c-a211-600eadb4540d/resource/c1282b6b-203e-4832-b0d8-a405872e4cad/download/health-and-safety-in-the-science-classroom.pdf
112. Taxonomy of cysts https://unesdoc.unesco.org/ark:/48223/pf0000136182
113. Abbe Flap - Springer Link https://link.springer.com/content/pdf/10.1007%2F978-3-642-23499-6_69.pdf
114. Abstracts cont - PMC - PubMed Central - NIH https://pmc.ncbi.nlm.nih.gov/articles/PMC7129916/

115. CSO (Canadian Society of Otolaryngology - Springer Link https://link.springer.com/article/10.1186/s40463-020-00476-9
116. 2018 Book NursingInCriticalCareSetting PDF https://www.scribd.com/document/451902256/2018-Book-NursingInCriticalCareSetting-pdf
117. Catastrofes Anestesia | PDF | Sleep Apnea https://www.scribd.com/document/421376004/catastrofes-anestesia
118. Plasma biology and plasma medicine (Part II) https://www.cambridge.org/core/books/plasma-medicine/plasma-biology-and-plasma-medicine/AFD8996F1808EA9FC6ABC3B68ADDC0D5
119. Detection of HAB species using lectin, antibody and DNA ... https://unesdoc.unesco.org/ark:/48223/pf0000136167
120. Proposed revisions to USP Chapter 797 for sterile ... https://dial.iowa.gov/media/6557/download?inline
121. The Practice Nurse - Springer Link https://link.springer.com/content/pdf/10.1007/978-1-4899-6874-6.pdf
122. The effects of acute hydrogen peroxide exposure on ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9979836/
123. Hydrogen peroxide at a concentration used during ... https://pubmed.ncbi.nlm.nih.gov/19107492/
124. Topical Silver Nitrate Application During Myringoplasty for . ... https://journals.lww.com/ijoo/fulltext/2019/25040/topical_silver_nitrate_application_during.1.aspx
125. Effect of Silver Nitrate and Epidermal Growth Factor on ... https://www.academia.edu/53935558/Effect_of_Silver_Nitrate_and_Epidermal_Growth_Factor_on_Nonhealing_Tympanic_Membrane_Perforations_A_Randomized_Controlled_Study
126. Effect of Silver Nitrate and Epidermal Growth Factor on ... https://www.researchgate.net/publication/330471305_Effect_of_Silver_Nitrate_and_Epidermal_Growth_Factor_on_Nonhealing_Tympanic_Membrane_Perforations_A_Randomized_Controlled_Study
127. A Study of Closure of Tympanic Membrane Perforations by ... https://pmc.ncbi.nlm.nih.gov/articles/PMC3477427/
128. Effect of pH and buffer composition on oxygen ... https://www.sciencedirect.com/science/article/abs/pii/S1742706122001994
129. The mechanism of pH-dependent hydrogen peroxide ... https://pubmed.ncbi.nlm.nih.gov/3421711/

130. [PDF] The effects of acute hydrogen peroxide exposure on ... https://www.semanticscholar.org/paper/The-effects-of-acute-hydrogen-peroxide-exposure-on-Francis/86bab645c5eb0e2bc3da0ea822e1d69b6b38c08c